Na Young Park

Na Young Park

Auto-generated profile, based on publicly available information

Na Young Park

Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Clinical Neurology
Verified
Journal Article
Open access
JHJae-Won Hyun
Jae-Won Hyun
HJHyunmin Jang
Hyunmin Jang
JYJaeBin Yu
JaeBin Yu
NPNa Young Park
Na Young Park
SKSu-Hyun Kim
Su-Hyun Kim
HKHo Jin Kim
Ho Jin Kim
To compare the characteristics of neuropathic pain in neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS). From 2016 to 2018, 500 patients with NMOSD and MS from 6 referral hospitals in Korea underwent pain investigation. After the patients with current pain were matched for sex ratio and disease duration as confounding factors, PainDETECT questionnaires were assessed in 99 NMOSD and 58 MS patients to investigate neuropathic pain. The short form of the Brief Pain Inventory from 74 patients with neuropathic pain component was also analysed. According to the PainDETECT questionnaire, mechanical allodynia (p=0.014) and thermal hyperalgesia (p=0.011) were more severe in NMOSD patients than in MS patients. Strong involvements (score >3) of the pain in domains of tingling/prickling sensation (p=0.024), mechanical allodynia (p=0.027), sudden pain attacks (p=0.018), and thermal hyperalgesia (p=0.002) were significantly more frequent in NMOSD compared to MS patients. Among the patients experiencing pain with a neuropathic component, total pain-related interference (p=0.045) scores were significantly higher in NMOSD patients than in MS patients. In daily life, pain interfered with normal work (p=0.045) and relationships with other people (p=0.039) more often in NMOSD patients than in MS patients. Although pain medication was prescribed more frequently in NMOSD patients, the percentage of patients experiencing medication-related pain relief was lower in those patients. The severity of neuropathic pain and the pain-related interference in daily life were greater in NMOSD patients than in MS patients. Individualized analgesic management should be considered based on a comprehensive understanding of neuropathic pain in these patients.

1 January 2019 in Journal of Clinical Neurology
Verified
Journal Article
Open access
SKSu-Hyun Kim
Su-Hyun Kim
YKYeseul Kim
Yeseul Kim
JJJi Yun Jung
Ji Yun Jung
NPNa-Young Park
Na-Young Park
HJHyunmin Jang
Hyunmin Jang
HKHo Jin Kim
Ho Jin Kim
Background and Purpose The anti-John-Cunningham virus (JCV)-antibody serostatus and index are used in the risk stratification of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with natalizumab. However, little information on these parameters is available for Asian countries. The purpose of this study was to determine the rate of seropositivity, index, and longitudinal index evolution in Korean patients with MS. Methods The antibody seroprevalence was analyzed in 355 samples from 187 patients with clinically isolated syndrome or MS using a second-generation, two-step, enzyme-linked immunosorbent assay. A 4-year longitudinal evaluation was applied to 66 patients. Results The overall antibody seroprevalence was 80% (n=149). Among antibody-positive patients, the index had a median value of 3.27 (interquartile range, 1.52-4.18), with 77% (n=114) and 56% (n=83) of patients having indices >1.5 and >3.0, respectively. The serostatus of 59 (89%) of the 66 patients did not change during the longitudinal analysis, while 3 (6%) of the 53 patients who were initially seropositive reverted to seronegativity, and 2 (15%) of the 13 patients who were initially seronegative converted to seropositivity. All patients with a baseline index >0.9 maintained seropositivity, and 92% of patients with a baseline index >1.5 maintained this index over 4 years. No patients developed PML (median disease duration, 8 years). Conclusions The seroprevalence and index of anti-JCV antibodies in Korean patients with MS may be higher than those in Western countries.

31 March 2012 in Journal of The Korean Society of Agricultural Engineers
Verified
Journal Article
Open access
SYSeung-Hwan Yoo
Seung-Hwan Yoo
JCJin-Yong Choi
Jin-Yong Choi
SLSang-Hyun Lee
Sang-Hyun Lee
YOYun-Gyeong Oh
Yun-Gyeong Oh
NPNa-Young Park
Na-Young Park

1 January 2020 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
WKWoojun Kim
Woojun Kim
EPEun Young Park
Eun Young Park
JHJae-Won Hyun
Jae-Won Hyun
SHSo-Young Huh
So-Young Huh
NPNa Young Park
Na Young Park
HKHo Jin Kim
Ho Jin Kim
Kim W, et al. J Clin Neurol. 2020 Apr;16(2):270-276. https://doi.org/10.3988/jcn.2020.16.2.270

16 November 2026 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Closed access
PDF file
SKSu-Hyun Kim
Su-Hyun Kim
HJHyunmin Jang
Hyunmin Jang
NPNa Young Park
Na Young Park
YKYeseul Kim
Yeseul Kim
SKSo-Yeon Kim
So-Yeon Kim
HKHo Jin Kim
Ho Jin Kim